NurExone Biologic Statistics

Total Valuation

NurExone Biologic has a market cap or net worth of CAD 49.63 million. The enterprise value is 46.26 million.

Market Cap	49.63M
Enterprise Value	46.26M

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

NurExone Biologic has 70.89 million shares outstanding. The number of shares has increased by 37.86% in one year.

Current Share Class	n/a
Shares Outstanding	70.89M
Shares Change (YoY)	+37.86%
Shares Change (QoQ)	+3.32%
Owned by Insiders (%)	6.68%
Owned by Institutions (%)	n/a
Float	66.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	12.48
P/TBV Ratio	12.55
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.09
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.68

Financial Position

The company has a current ratio of 6.49, with a Debt / Equity ratio of 0.01.

Current Ratio	6.49
Quick Ratio	6.40
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	-471.20

Financial Efficiency

Return on equity (ROE) is -232.06% and return on invested capital (ROIC) is -143.94%.

Return on Equity (ROE)	-232.06%
Return on Assets (ROA)	-105.50%
Return on Capital (ROIC)	-143.94%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +132.26% in the last 52 weeks. The beta is -0.06, so NurExone Biologic's price volatility has been lower than the market average.

Beta (5Y)	-0.06
52-Week Price Change	+132.26%
50-Day Moving Average	0.68
200-Day Moving Average	0.63
Relative Strength Index (RSI)	45.03
Average Volume (20 Days)	43,469

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-5.73M
Pretax Income	-5.72M
Net Income	-5.72M
EBITDA	-5.69M
EBIT	-5.73M
Earnings Per Share (EPS)	-0.10

Full Income Statement

Balance Sheet

The company has 3.41 million in cash and 41,879 in debt, giving a net cash position of 3.37 million or 0.05 per share.

Cash & Cash Equivalents	3.41M
Total Debt	41,879
Net Cash	3.37M
Net Cash Per Share	0.05
Equity (Book Value)	3.96M
Book Value Per Share	0.06
Working Capital	3.23M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.11 million and capital expenditures -905,137, giving a free cash flow of -6.02 million.

Operating Cash Flow	-5.11M
Capital Expenditures	-905,137
Free Cash Flow	-6.02M
FCF Per Share	-0.08

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NurExone Biologic does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-37.86%
Shareholder Yield	-37.86%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a